Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> ​
Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.
Astonishingly, after a median follow-up of 10 years, the prostate cancer mortality rate, which was the primary endpoint of the study, was only 1%, Mason says.
Digging a little deeper, Mason says, the overall mortality was only 10% at 10 years. But, if you look at clinical disease progression, there was a difference. Curative treatments, including surgery or radiotherapy, do reduce the likelihood of disease progression by about half. That is a big effect, however, this is a phenomenon that only affects a minority of men, Mason says.
The results of PROTECT should not be used as an argument to say we should not be treating men with deferred treatment, as most men do not require treatment. However, whether or not it is right to defer treatment for an individual man depends on the patient’s perception of the risk of disease progression versus the side effects of immediate treatment with surgery or radiotherapy.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More